(ACCD) Accolade - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00437E1029
ACCD: Healthcare, Technology, Benefits, Advocacy, Navigation, Consulting
Accolade, Inc. (NASDAQ:ACCD) is a U.S.-based healthcare technology company that provides personalized, technology-driven solutions to help individuals navigate the complexities of the healthcare system and workplace benefits. Founded in 2007 and headquartered in Seattle, Washington, the company leverages a cloud-based platform that integrates intelligent technology with multimodal support from a diverse team of healthcare professionals. This includes registered nurses, physician medical directors, pharmacists, behavioral health specialists, womens health experts, case management specialists, and primary care physicians. Accolade’s platform is designed to simplify healthcare navigation, improve care outcomes, and optimize benefit utilization for employees and their families.
The company’s offerings include medical opinion services for commercial customers, navigation and care advocacy solutions, and medical consultations that connect patients with condition-specific specialists for both adult and pediatric care. Additionally, Accolade provides primary care and mental health support solutions, addressing a wide range of healthcare needs. Its target market is employers seeking to provide a centralized, user-friendly platform for employees to manage their health, healthcare, and benefits seamlessly.
From a technical perspective, ACCD has shown a short-term upward trend, with its 20-day simple moving average (SMA) at 6.91, slightly above its last price of 6.96. However, the 50-day SMA (5.79) and 200-day SMA (4.77) indicate a longer-term downtrend. The average true range (ATR) of 0.15 reflects relatively low volatility in recent trading activity.
On the fundamental side, Accolade has a market capitalization of $564.40 million, with a price-to-book (P/B) ratio of 1.80 and a price-to-sales (P/S) ratio of 1.26. The company currently reports a negative return on equity (RoE) of -57.60%, reflecting ongoing challenges in achieving profitability. Its forward P/E ratio is 0.00, indicating that investors are not currently pricing in near-term earnings growth.
3-Month Forecast: Based on the intersection of technical and fundamental data, ACCD is likely to trade within a narrow range in the near term, with potential resistance at the 50-day SMA (5.79) and support at the 200-day SMA (4.77). The low ATR of 0.15 suggests limited volatility, but the negative RoE and lack of profitability could weigh on investor sentiment. If the stock breaks above its 50-day SMA, it may test the $7.50 level, while a breach below the 200-day SMA could push it toward $4.00. The company’s ability to improve its financial health and demonstrate progress toward profitability will be key drivers of its performance in the next quarter.
Additional Sources for ACCD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACCD Stock Overview
| Market Cap in USD | 570m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception | 2020-07-02 |
ACCD Stock Ratings
| Growth 5y | 5.02% |
| Fundamental | -22.5% |
| Dividend | 0.0% |
| Rel. Strength Industry | -27.6 |
| Analysts | 3.42/5 |
| Fair Price Momentum | 4.26 USD |
| Fair Price DCF | - |
ACCD Dividends
No Dividends PaidACCD Growth Ratios
| Growth Correlation 3m | 93.6% |
| Growth Correlation 12m | -39.7% |
| Growth Correlation 5y | -84.3% |
| CAGR 5y | 71.53% |
| CAGR/Max DD 5y | 0.76 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | -28.96 |
| Beta | -0.34 |
| Volatility | 8.00% |
| Current Volume | 518.8k |
| Average Volume 20d | 961.7k |
As of March 15, 2025, the stock is trading at USD 6.98 with a total of 518,849 shares traded.
Over the past week, the price has changed by +0.14%, over one month by +1.16%, over three months by +100.00% and over the past year by -26.99%.
Neither. Based on ValueRay Fundamental Analyses, Accolade is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -22.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACCD as of March 2025 is 4.26. This means that ACCD is currently overvalued and has a potential downside of -38.97%.
Accolade has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold ACCD.
- Strong Buy: 2
- Buy: 1
- Hold: 9
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ACCD Accolade will be worth about 4.6 in March 2026. The stock is currently trading at 6.98. This means that the stock has a potential downside of -34.1%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7 | 0.7% |
| Analysts Target Price | 7.1 | 1.1% |
| ValueRay Target Price | 4.6 | -34.1% |